Drug Profile

RR 001

Alternative Names: AD-PC sTRAIL; RR001

Latest Information Update: 15 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rigenerand
Class Antineoplastics; Gene therapies
Mechanism of Action Cell replacements; TNF-related apoptosis-inducing ligand replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity No

Highest Development Phases

Phase I/II Adenocarcinoma

Most Recent Events

28 Jun 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in Italy (Parenteral)
14 Jan 2021 Rigenerand plans a first-in-human phase I trial for Pancreatic cancer in Italy in the second quarter of 2021
02 Jun 2020 The Italian Medicine Authority approves clinical trial application for RR 001 in Pancreatic cancer (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com